title: Beneficial effect of low molecular weight heparin on the hemodialysis model in dogs.
abstract: The effect of FR-860, one of low molecular weight heparins, was investigated on the hemodialysis model in dogs for comparison with that of conventional unfractionated heparin (UF-heparin). In a bolus injection model, FR-860 at 12.5-100 U/kg prolonged the dialysis time (the time until the arterial circuit pressure reaching 500 mmHg) in a dose-dependent manner and UF-heparin at 50 U/kg also prolonged it. Additionally, FR-860 (12.5-50 U/kg/hr) and UF-heparin (25 and 50 U/kg/hr) continuously inhibited the rise of the arterial circuit pressure in an infusion model. In both models, the efficacy of FR-860 was more potent than that of UF-heparin. FR-860 and UF-heparin decreased the amount of blood loss remaining in the dialyzer in the infusion model. During hemodialysis, both FR-860 and UF-heparin showed activated plasma anti-F.Xa activity, prolongation of aPTT and such of thrombin time in a dose-dependent manner in those models. However, FR-860 was higher in anti-F.Xa activity and weaker in prolongation of aPTT and thrombin time than UF-heparin. These results suggest that FR-860 is more beneficial in in efficacy and higher in safety against the bleeding risk than UF-heparin hemodialysis.
authors.affiliation: Central Research Laboratories, Kissei Pharmaceutical Co. Ltd., Matsumoto, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hamano
authors.forename: H
authors.initials: H
authors.lastname: Komatsu
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Oguma
authors.forename: N
authors.initials: N
authors.lastname: Sakuragawa
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D065427:Factor Xa Inhibitors; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D010314:Partial Thromboplastin Time; D006435:Renal Dialysis; D013918:Thrombin Time
chemical_list: D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin